<DOC>
	<DOCNO>NCT01055223</DOCNO>
	<brief_summary>Treatment thiazolidinediones ( TZD ) recently report possibly increase risk fracture randomize trial explore efficacy rosiglitazone ( RSG ) , metformin , glyburide encompass 4360 patient type 2 diabetes . It hypothesize spironolactone , diuretic broadly use treatment fluid retention edema associate TZD , potential protective effect bone fracture . However , knowledge , test diabetic patient treat TZD . Amiloride another diuretic share spironolactone anti mineralocorticoid ion gate channel activity analyse study regard possible protective effect bone fracture combination TZD . This study nest case-control study conduct among type 2 diabetes subject expose TZD . The study aim explore risk fracture reduce among type 2 diabetic subject expose spironolactone TZD . The study compare odds low impact fracture , hand , foot , upper arm , wrist , hip fracture incidence subject treat TZD+spironolactone TZD+amiloride compare subject treat TZD . The study population consist type 2 diabetes patient age 18 -65 year old expose TZD . To eligible study , subject must least one International Classification Disease ( ICD ) -9 code type 2 diabetes least 6 month least 12 month exposure TZD ( rosiglitazone [ RSG ] , pioglitazone [ PIO ] troglitazone ) follow-up time available database .</brief_summary>
	<brief_title>Fracture Risk With Thiazolidinediones</brief_title>
	<detailed_description>Patients recruit enrolled study . This study retrospective observational study . Data medical record insurance claim database anonymised use develop patient cohort . All diagnosis treatment record course routine medical practice .</detailed_description>
	<mesh_term>Fractures , Bone</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Spironolactone</mesh_term>
	<mesh_term>Amiloride</mesh_term>
	<mesh_term>Troglitazone</mesh_term>
	<mesh_term>2,4-thiazolidinedione</mesh_term>
	<criteria>At least one ICD9 code type 2 diabetes At least 6 month least 12 month exposure TZD ( RSG , PIO troglitazone ) followup time available database ( The subject 's study period begin date define early date first TZD prescription . Subjects include study require least six month followup time database prior first TZD prescription ) Subjects diagnosis Paget 's disease osteomalacia A history fracture , osteoporosis cancer prior first prescription TZD ( study begin date )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>thiazolidinediones</keyword>
	<keyword>rosiglitazone</keyword>
	<keyword>amiloride</keyword>
	<keyword>pioglitazone</keyword>
	<keyword>fracture</keyword>
	<keyword>Spironolactone</keyword>
</DOC>